Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346. The study will run in Canada and is expected to conclude in December 2018.
“Veristat is excited to continue our support of Antibe Therapeutics’ ATB-346 program. We are providing full-service clinical support for Antibe’s current and upcoming Phase II dose-ranging efficacy studies,” said Shaheen Limbada, SVP Global Clinical Operations at Veristat, “We look forward to strengthening our long-term partnership with Antibe with continued support of their clinical development programs.”
Veristat’s full-service clinical development solutions are ideal for emerging and small to mid-size biopharmaceutical companies. We deliver uncompromised value and impact to our clients as we guide them from early phase trial planning and design, through to trial execution, regulatory submission support through to post-approval.